“Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality

Borderline personality disorder (BPD) is an extremely disabling condition that affects almost every dimension of a patient’s life. The S-enantiomer of ketamine (esketamine) was approved by the Food and Drug Administration (FDA) in 2019 in conjunction with an oral antidepressant for the management of...

Descripción completa

Detalles Bibliográficos
Autores principales: Nandan, Neethu K, Soni, Puneet K, Parsaik, Ajay, Hashmi, Aqeel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Psychiatry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156400/
https://www.ncbi.nlm.nih.gov/pubmed/35664413
http://dx.doi.org/10.7759/cureus.24632

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156400/
https://www.ncbi.nlm.nih.gov/pubmed/35664413
http://dx.doi.org/10.7759/cureus.24632

Ejemplares similares